Business Context and Reporting Period
This Form 8-K Current Report was filed by Assembly Biosciences, Inc. on March 12, 2018, covering events that occurred on March 8, 2018. The filing primarily addresses significant changes in executive leadership and board composition.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements and equity grants.
- New CFO/COO Base Salary: $425,000 annually.
- Target Performance Bonus: 40% of base salary.
- Equity Grant (CFO/COO): Option to purchase 220,000 shares of common stock.
- Equity Grant (New Director): Option to purchase 20,000 shares of common stock.
Material Changes
The following material changes were effective March 8, 2018:
- Executive Departure and Appointment: Graham Cooper was appointed Chief Financial Officer (CFO) and Chief Operating Officer (COO), replacing David Barrett. Mr. Barrett will transition to a strategic advisor role and later to a consulting role.
- Board Expansion: The Board of Directors increased its size from eight to nine members.
- New Director Appointment: Helen S. Kim was appointed as an independent, nonemployee director and member of the Science & Technology Committee.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business performance. Key contractual terms and contingencies include:
- Severance Provisions (Change of Control): If terminated without cause, for good reason, or due to disability/death within 12 months of a change of control, Mr. Cooper is eligible for 18 months of base salary, 1.5x target bonus, and immediate full vesting of equity awards.
- Severance Provisions (Standard Termination): If terminated without cause, for good reason, or due to disability outside the change of control window, Mr. Cooper is eligible for 12 months of base salary and acceleration of equity awards that would have vested over the next 12 months.
- Equity Vesting Schedule (CFO/COO): The 220,000 share option vests one-third on the first anniversary (March 8, 2019) and the remaining two-thirds in 24 equal monthly installments, fully vesting on March 8, 2021.
- Equity Vesting Schedule (Director): The 20,000 share option vests in three equal annual installments.
Investor Verification Checklist
- Verify the terms of the Employment Agreement for Graham Cooper, which will be filed as an exhibit to the Form 10-Q for the period ended March 31, 2018.
- Confirm the transition timeline for David Barrett from employee to strategic advisor to consultant.
- Review the press release (Exhibit 99.1) for additional context on the leadership changes.
- Monitor future filings for the impact of the new CFO/COO on the company's financial strategy and capital allocation.